The CAR-T That Ditched Viruses Entirely

A Target That Plays Nice With Healthy Cells

The other half of TCX-001's story is its target: Siglec-6, a protein found on the surface of leukemia cells.

Targeting AML with CAR-T has been notoriously difficult. Most AML surface markers (like CD33 or CD123) also show up on normal blood-forming stem cells. Killing those means you wipe out the patient's ability to make new blood cells, often requiring a bone marrow transplant to recover. It's like trying to remove weeds from a garden by torching the whole yard.

Siglec-6 offers a way around this problem. In preclinical studies, the protein was found on roughly 60% of AML blasts and leukemic stem cells (the self-renewing cells that drive relapse), while being essentially absent from normal blood-forming stem cells. In mouse models, Siglec-6-targeted CAR-T cells cleared leukemia and extended survival without destroying the bone marrow's ability to regenerate.

For CLL, the logic is similar. Siglec-6 appears on leukemic B cells but has limited expression on healthy B cells, which could mean less collateral immune damage compared to CD19-targeted therapies that wipe out all B cells indiscriminately.

A Tiny Company With Big Ambitions

T-CURX is a spin-out from University Hospital Würzburg, co-founded by Prof. Michael Hudecek (CMO), Prof. Christoph Rader, and Dr. Ulf Grawunder (CEO). The company has raised approximately €25 million in seed financing plus non-dilutive grants from Germany's federal research ministry and other public sources. A third-party database also reports a Series A round of about $20 million in late 2025, led by BiomedVC.

With this Swissmedic clearance, T-CURX formally transitions from preclinical-stage company to clinical-stage biotech. They've also partnered with Kytopen to access its Flowfect continuous-flow electroporation technology, another piece of the non-viral manufacturing puzzle.

Where This Fits in the Bigger Picture

The AML CAR-T landscape is crowded with early attempts but empty of approvals. There are roughly 75 registered AML CAR-T trials, with about 71% still in Phase 1. No CAR-T product has ever been approved for AML in any market. CLL recently got its first CAR-T approval with Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a CD19-directed therapy.

TCX-001 is swimming against two currents at once: a disease area (AML) where CAR-T hasn't cracked the code yet, and a manufacturing approach (non-viral) that most of the industry hasn't adopted. That's either brave or foolish, depending on the data.

The Phase 1 trial will test three dose levels, ranging from 100,000 to 1 million CAR-T cells per kilogram of body weight. Primary goals are safety, tolerability, and finding the right dose for Phase 2. Secondary endpoints include response rates, how long those responses last, and whether the CAR-T cells expand and persist in patients.

Why Switzerland, and Why Now?

Swissmedic's new fast-track pilot program (launched in mid-2025) cuts review times for first-in-human trials addressing high medical need from 60 days down to 40 days, making Switzerland one of the fastest regulatory on-ramps in the world for novel therapies. The FDA's IND review takes 30 days on paper but often involves extensive pre-submission dialogue. EU procedures under the Clinical Trials Regulation can stretch past 50 days for complex gene therapies.

For a small European biotech, starting in Switzerland is a smart regulatory play: fast approval, world-class clinical infrastructure at University Hospital Zürich, and a clear pathway to expand into the EU via a CTIS application to the European Medicines Agency.

The Bottom Line

TCX-001 is one clinical trial, in 23 patients, at one hospital. It will be years before anyone knows if this therapy actually works in humans. But the significance isn't just about one drug.

If non-viral CAR-T manufacturing proves safe and effective at clinical scale, it could break open the bottleneck that keeps cell therapy expensive and inaccessible. Sleeping Beauty transposon systems cost a fraction of viral vectors. They're simpler to produce. They're easier to decentralize.

The seven approved CAR-T products on the market today all rely on viral vectors. TCX-001 is betting that the next generation won't need them. That's a bold bet, and one worth watching.

AstraZeneca Just Spent $2.1 Billion to Pick a Fight With Merck

AstraZeneca signed a $2.1 billion licensing deal with Sino Biopharmaceutical for a COPD drug designed to challenge Merck's blockbuster Ohtuvayre. With stronger early lung function data and AstraZeneca's massive respiratory salesforce behind it, the PDE3/PDE4 market just became a two-horse race.